Technical Analysis for ABBV - AbbVie Inc.

Grade Last Price % Change Price Change
grade B 99.57 0.83% 0.82
ABBV closed up 0.83 percent on Friday, June 15, 2018, on 2.37 times normal volume. It was able to find support at its 50 day moving average. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Flat
See historical ABBV trend table...

Date Alert Name Type % Chg
Jun 15 50 DMA Support Bullish 0.00%
Jun 15 Stochastic Buy Signal Bullish 0.00%
Jun 15 Upside 200 DMA Break Bullish 0.00%
Jun 15 Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Jun 15 Strong but Oversold Other 0.00%
Jun 15 Oversold Stochastic Weakness 0.00%
Jun 14 200 DMA Resistance Bearish 0.83%
Jun 14 Crossed Above 50 DMA Bullish 0.83%
Jun 14 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.83%
Jun 14 NR7 Range Contraction 0.83%

Older signals for ABBV ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

AbbVie Inc., a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. Its product portfolio includes a range of adult and pediatric pharmaceuticals, including HUMIRA, a biologic therapy administered as a subcutaneous injection to treat various autoimmune diseases; Synthroid used in the treatment of hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has collaboration with Alvine Pharmaceuticals, Inc. to develop a oral treatment for patients with celiac disease. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013.AbbVie Inc. operates independently of Abbott Laboratories.
Is ABBV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 125.86
52 Week Low 68.8993
Average Volume 8,696,938
200-Day Moving Average 98.8882
50-Day Moving Average 98.753
20-Day Moving Average 101.019
10-Day Moving Average 99.265
Average True Range 2.0955
ADX 18.18
+DI 19.11
-DI 24.26
Chandelier Exit (Long, 3 ATRs ) 100.9635
Chandelier Exit (Short, 3 ATRs ) 103.7965
Upper Bollinger Band 106.6785
Lower Bollinger Band 95.3595
Percent B (%b) 0.37
BandWidth 11.204823
MACD Line -0.5999
MACD Signal Line -0.2939
MACD Histogram -0.306
Fundamentals Value
Market Cap 158.73 Billion
Num Shares 1.59 Billion
EPS 4.07
Price-to-Earnings (P/E) Ratio 24.46
Price-to-Sales 5.35
Price-to-Book 23.76
PEG Ratio 1.00
Dividend 2.56
Dividend Yield 2.57%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 102.36
Resistance 3 (R3) 102.15 101.00 101.90
Resistance 2 (R2) 101.00 100.29 101.11 101.74
Resistance 1 (R1) 100.29 99.85 100.65 100.50 101.58
Pivot Point 99.14 99.14 99.32 99.25 99.14
Support 1 (S1) 98.43 98.43 98.79 98.64 97.56
Support 2 (S2) 97.28 97.99 97.39 97.40
Support 3 (S3) 96.57 97.28 97.25
Support 4 (S4) 96.78